Literature DB >> 8690406

Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes.

M Tapner1, C Liddle, B Goodwin, J George, G C Farrell.   

Abstract

Administration of interferons of both the gamma and alfa/beta classes down-regulates hepatic cytochrome P450 (CYP) genes when administered to humans or rats. In male rats, interferons decrease expression of CYP3A2 at a pretranslational level, but because interferons also release other cytokines in vivo, it is unclear whether this is a direct effect on hepatocytes. We therefore examined the effects of rat recombinant interferon gamma (IFN-gamma) on CYP3A2, other 3A genes, and 2C11 in stable primary cultures of male rat hepatocytes. Hepatocytes were cultured on matrigel in Williams' E, and messenger RNAs (mRNAs) for 3A2, 3A1-like CYPs, and 2C11 mRNA were determined by RNase protection assays. CYP3A and 2C11 proteins were immunoquantified, and their catalytic activities were estimated by testosterone hydroxylation pathways. In control cells, 3A2 mRNA decreased initially but then recovered, and stable levels (15% of freshly isolated cells) were attained between days 3 and 7. Phenobarbital increased 3A2 mRNA to 60-120% values of freshly isolated cells, and mRNA for 3A1-like CYPs were increased 20-fold. In both control and phenobarbital-treated hepatocytes, rat recombinant IFN-gamma (33 U/mL) reduced mRNA for 3A2 and 3A1-like CYPs, as well as 3A protein and testosterone 6 beta-hydroxylase activity. Interferon had no effect on CYP2C11 at mRNA or protein levels in untreated cells, although a reduction in 2C11 protein was evident in phenobarbital-treated cultures. It is concluded that interferon directly alters expression of constitutive and inducible CYP3A genes in well-differentiated male rat hepatocytes in culture, but has no effect on constitutive expression of CYP2C11.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690406     DOI: 10.1002/hep.510240213

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.

Authors:  Zhipeng Meng; Xiaoqiong Wang; Yichao Gan; Yunfeng Zhang; Hong Zhou; Carl Van Ness; Jun Wu; Guiyu Lou; Hua Yu; Chao He; Rongzhen Xu; Wendong Huang
Journal:  J Hepatol       Date:  2012-06-21       Impact factor: 25.083

Review 2.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

3.  Involvement of CYP1B1 in interferon γ-induced alterations of epithelial barrier integrity.

Authors:  Mireille Alhouayek; Sandra Gouveia-Figueira; Marie-Louise Hammarström; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2018-02-04       Impact factor: 8.739

4.  Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice.

Authors:  Beatrice A Nyagode; Choon-Myung Lee; Edward T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

Review 5.  Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.

Authors:  Natasha T Snider; Vyvyca J Walker; Paul F Hollenberg
Journal:  Pharmacol Rev       Date:  2010-02-04       Impact factor: 25.468

6.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

7.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients.

Authors:  Edoardo Giannini; Alberto Fasoli; Federica Botta; Paola Romagnoli; Federica Malfatti; Bruno Chiarbonello; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

9.  Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.

Authors:  E G Brain; L J Yu; K Gustafsson; P Drewes; D J Waxman
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.

Authors:  Beatrice A Nyagode; Roya Jahangardi; Matthew D Merrell; Malú G Tansey; Edward T Morgan
Journal:  Pharmacol Res Perspect       Date:  2014-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.